Sign up
ELDN

Eledon Pharmaceuticals Inc (NASDAQ: ELDN)

Healthcare

$2.03+0.05 (+2.53%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. ELDN rose 2.53% in the Nov 18 session to $2.03. The borrow fee is 0.41%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $12.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationBroadly in line with peers

P/B 5.8× vs peer median 2.6×

MomentumNeutral

RSI (14) 44.0 (overbought above 70, oversold below 30)

Trend—

—

Short interest10.7% of float

FINRA settlement Oct 30, 2026

ELDN price chart

Price $2.03 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$2.05Nov 18, 2026 session
Previous close
$1.98Nov 17, 2026 close
Day range
$1.96 – $2.10Nov 18, 2026 session
52-week range—
Volume
1.14MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

ELDN · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide57High Tide—
How the scores work →

How ELDN compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. One-year return was 25.3%, higher than 78% of 522 peers.Peer median −28.4% · As of Nov 17, 2026

Points of caution

  1. Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026

Valuation

Broadly in line with peers

  • Price/sales—13.88×

    Not ranked: only 408 of 592 peers report it

  • Forward P/E5.39×14.97×

    Not ranked: only 193 of 592 peers report it

  • Price/book5.80×2.57×

    Higher than 74% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin—78.4%

    Not ranked: only 247 of 592 peers report it

  • Operating margin0.0%0.0%

    Higher than 26% of 442 peers

  • Net margin0.0%0.0%

    Higher than 19% of 583 peers

  • Return on equity−105.7%−67.8%

    Higher than 36% of 554 peers

Growth

Growth metrics are lower than most peers.

  • Quarterly sales growth, year over year0.0%0.0%

    Higher than 32% of 592 peers

  • 5-year sales growth rate—11.3%

    Not ranked: only 140 of 592 peers report it

Balance sheet

Balance sheet metrics are higher than most peers.

  • Current ratio6.304.99

    Higher than 58% of 498 peers

  • Debt/equity (total borrowings)—0.23

    Not ranked: only 117 of 592 peers report it

Momentum

Returns are mixed versus peers.

  • 1-year return+25.3%−28.4%

    Higher than 78% of 522 peers

  • 6-month return−47.1%−26.6%

    Higher than 31% of 545 peers

  • 3-month return−42.3%−29.4%

    Higher than 33% of 558 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
1Buy
0Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$12.00
Average$12.00
High$12.00

As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.19−$0.03—
Q2 2026−$0.15−$0.27—
Q1 2026−$0.26−$0.33—
Annual 2025—−$0.52—
Q3 2025—−$0.21—
Q2 2025—−$0.13—
Q1 2025—−$0.08—
Annual 2024−$0.33−$0.75—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FMILLENNIUM MANAGEMENT LLCClosed position$013F filing
13FAQR CAPITAL MANAGEMENT LLCIncreased position$531.0K13F filing
13FRENAISSANCE TECHNOLOGIES LLCReduced position$75.8K13F filing
13FMILLENNIUM MANAGEMENT LLCOpened position$35.9K13F filing
13FAQR CAPITAL MANAGEMENT LLCOpened position$90.9K13F filing
13FRENAISSANCE TECHNOLOGIES LLCReduced position$267.3K13F filing
13FCITADEL ADVISORS LLCClosed position$013F filing
13FMILLENNIUM MANAGEMENT LLCClosed position$013F filing
13FRENAISSANCE TECHNOLOGIES LLCIncreased position$904.4K13F filing
13FCITADEL ADVISORS LLCIncreased position$413.2K13F filing
All smart-money activity →

News and press releases

News and press releases are not available.

All ELDN news →

Company profile

CEO
—
Headquarters
—
Employees
—
IPO date
—
Sector
Healthcare
Industry
—

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.